Author Topic: SCLP Cancer vaccines  (Read 8760 times)

0 Members and 1 Guest are viewing this topic.

Offline Roger

  • posting on moderation row
  • Korat forum specialist
  • *
  • Posts: 1572
  • Thanked: 43 times
  • Karma: 1
Re: SCLP Cancer vaccines
« Reply #30 on: October 15, 2015, 02:24:49 PM »
Scancell's progress continues - one new USA based Non-exec Director and one USA based advisor appointed this week.
Biotech values in the USA, though currently slumping, are massive compared to the UK and it looks as if the BoD are going to take this one over the water for further development.
The current share price of Scancell is just laughable - 22.75 pence. Just low because the AIM market functions badly and our Board keep a lowish profile.
That said there is an article today in proactiveinvestors.co.uk - you can find it on the homepage under 'Ambitious Scancell ....'. It's a good read and will explain Scancell a lot better than I can.
Immunotherapy IS going to take over in the field of cancer treatment. You'll read many big stories in the Press but Scancell have a successful 'off the shelf' cancer vaccine with no toxicity and therefore no real side effects.
The 'Immunobody' platform is a plug and play system for vaccines and has been described as the 'universal antigen delivery system' allowing many different cancers to be addressed. SCIB1 the first vaccine soon going into Phase 3 trials is being described now as 'preventing the re-occurence of melanoma'. Do you know how fantastic that is ? Melanoma is brutal just brutal.
And the Moditope platform is ready  in 2016 for trials in latest stage cancers.
It's the Scancell AGM this week and many think that an announcement re. a Phase 3 collaboration with big Pharma and hopefully a 'liquidity event' will be forthcoming.
Keep well all.

 

Offline Roger

  • posting on moderation row
  • Korat forum specialist
  • *
  • Posts: 1572
  • Thanked: 43 times
  • Karma: 1
Re: SCLP Cancer vaccines
« Reply #31 on: October 15, 2015, 02:52:49 PM »
When I returned to my other BB, Scancell, I see there is also a 5 minute interview on the 'proactive' website, with our CEO Richard Goodfellow and he talks openly about the possibility of a NASDAQ listing. Exciting times.
Sorry - my 'Do you know' sentence in the last post looks a bit patronising. But fantastic it is ! I'm a bit excited about this. ATB
 

Offline Roger

  • posting on moderation row
  • Korat forum specialist
  • *
  • Posts: 1572
  • Thanked: 43 times
  • Karma: 1
Re: SCLP Cancer vaccines
« Reply #32 on: November 07, 2015, 11:14:42 AM »
No announcement was forthcoming at the recent Scancell AGM. Stalwart investors believe that the BoD are hamstrung by the confidentiality of discussions going on but the Share Price fell badly, on very small volumes - one of the vagaries of the AIM market.
The science is unchanged with amazing results on Stage 3/4 Melanoma patients, some of whom are alive after nearly 4 years. We are awaiting an update on a higher dose cohort (8mg) of patients who had showed immediately a 10 times response over the 4 mg dose. 
So there it is - resolve needed for long term investors such as myself ! With the share price stuck at around 16 pence Scancell IMO is an amazing investment prospect.
As for me, eating humble pie ATM but 100% confident still.
There was good news worldwide last week when a last ditch attempt to save a baby girl from leukaemia using Immunotherapy, (Car-T) led to an apparent full recovery. One patient ! No conclusions really possible from a one-off pre-clinical punt but SCLP still struggle for publicity !
Strange world.
 

Offline Roger

  • posting on moderation row
  • Korat forum specialist
  • *
  • Posts: 1572
  • Thanked: 43 times
  • Karma: 1
Re: SCLP Cancer vaccines
« Reply #33 on: November 08, 2015, 07:08:21 AM »
A really interesting article about the development of CAR-T immunotherapy for treating cancer can be found on lse.co.uk enter SCLP. A post by 'Crumbs' 15.13 yesterday links to 'Seeking Alpha'. Though quite technical it's very thorough and well worth a read and when you see the valuation on these Biotech Companies it gives perspective to the potential in what SCLP are doing. And SCLP valued at around £50 million atm.
I wish all these Companies the best luck BUT they do not have two plug and play platforms for cancer vaccines with low cost manufacture, no side effects, no toxicity and able to address a high percentage of patients.
GLA
 

Offline Roger

  • posting on moderation row
  • Korat forum specialist
  • *
  • Posts: 1572
  • Thanked: 43 times
  • Karma: 1
Re: SCLP Cancer vaccines
« Reply #34 on: February 11, 2018, 09:16:32 AM »
Linking in with the last post here some time ago, Juno a CAR-T Company in the USA was sold recently for $9 billion. Scancell's current valuation is about £30 million and the share price is now around 12 pence ! $9 billion would make the SP £20 or thereabouts LOL  :spin

I posted this elsewhere but for anyone interested, a paste here might give continuity :-

Just an update for anyone interested - Scancell's 2nd platform - Moditope 3
In a nutshell, 144 teams entered for CRUK's Grand Challenge - up to £20 million research grants.
Scancell are on the shortlist of 10. Their topic for the challenge will be Modi3 and Scancell's Prof Lindy Durrant, will lead a team of 15 eminent Oncologist/Scientists in preparing the paper in cooperation with Genentech, (a major Biotech owned by Roche), BioNTech in Germany who are using Modi to adapt CAR-T type therapy, and ISA Pharma of Germany. Pundits say that Moditope, taking away 100% of 'heavy tumour load' in pre-clinical work, can be an industry in itself. Share price 12 pence !

Official statements :-

''Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is proud to announce that an international, multi-disciplinary team of the leading cancer immunotherapy scientists in Europe and the US, led by Prof. Lindy Durrant, Chief Scientific Officer of Scancell, and in partnership with Genentech, BioNtech and ISA pharmaceuticals1, has been shortlisted to the final stages of Cancer Research UK's Grand Challenge2 - an ambitious series of £20 million global grants tackling some of the toughest questions in cancer research.  The team will collaborate on a project entitled "Project Blueprint: Eradicating established tumours with unique cancer vaccines".

Project Blueprint aims to eliminate tumours by treating patients with specific vaccines.  Prof. Lindy Durrant will lead an international world-class team to investigate the full potential of the tumour vaccine concept by building blueprints for an effective therapy for patients with most types of cancer.  The project focus will be on head and neck cancer, glioblastoma, lung, and pancreatic cancer - all of which currently have a poor prognosis - in which treatment with Modi-3, a product generated from Scancell's Moditope® platform will be assessed alongside vaccines targeting new mutations within individual patients' tumours
.''

And :-

'Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, notes that European Patent Office has announced its intention to grant Scancell's application for a European patent for its Moditope® immunotherapy platform.

This case is key to the protection of the Company's pipeline of Moditope® vaccines for the treatment of cancer and will provide commercial exclusivity in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.  Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

Cliff Holloway, Chief Executive Officer of Scancell, commented:
"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate.  This is a key case for the Company as we progress development of our Moditope® platform and provides further protection for Scancell's innovative cancer vaccine technologies."

*       *       *       *

Me again - Scancell now arguably have 4 platforms for cancer treatment.

Immunobody and Immunobody combo with checkpoint inhibitor
An Immunobody trial, SCIB1 for melanoma - 16 of 18 resected Patients with a prognosis of months, are alive after 5 years or more. In pre-clinical trials in combo - almost 100% of cancers were halted.

Moditope
Moditope with TCR therapy (BioNTech)
In pre clinical studies, Moditope took away 100% of heavy tumour load and Moditope it seems, can be engineered to address most cancers.
(There's some real science here, a wide Patent is shortly to be granted).

You can read the Scancell news on LSE.co.uk/SCLP under the header 'RNS'.

ATB
 

 



Thailand
Statistics